SAGE Therapeutics Presents New Data Identifying Highly Selective, Oral Compounds and Novel Approach for the Treatment of Chronic Epilepsies
SAGE's Novel Approach to Treatment of CNS Disorders to be Highlighted at Leading
Industry and Scientific Conferences
SAGE Therapeutics is building a neuroscience product focused company like no other, developing breakthrough therapeutics for diseases and conditions with tremendous unmet need, including status epilepticus, anesthesia, Fragile X and traumatic brain injury. The company’s proprietary Positive and Negative Allosteric Modulator (PANAM) platform leverages extensive chemistry expertise to enable the efficacious yet safe allosteric modulation of GABAA and NMDA receptors to restore the balance of activity that is disrupted in a variety of central nervous system (CNS) disorders. As a result, SAGE has built a robust product pipeline initially focused on acute and orphan CNS indications with clinically validated targets and accelerated development timelines – enabling us to bring important medicines to patients rapidly.